A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia
收藏DataCite Commons2025-03-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009928/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Background:
- Moxetumomab pasudotox is an experimental non-chemotherapy cancer treatment drug. It targets
CD22, a molecule on the surface of essentially all hairy cell leukemia cells. Moxetumomab
pasudotox binds to CD22, goes into the cell, and releases a toxin which kills the cell. In a
phase I trial it had activity in relapsed/refractory hairy cell leukemia with safety profile
supporting further clinical study (http://ncbi.nlm.nih.gov/pubmed/22355053). This is a phase
III multicenter trial designed to confirm these results.
提供机构：
Vivli
创建时间：
2024-04-02
